by Peter Ciszewski | Jun 24, 2020
Othman Al-Sawaf, MD of the University Hospital of Cologne discusses how the results from the multicenter, open-label, randomized, phase 3 CLL14 clinical trial. As Dr. Al-Sawaf, explains in this video, the trial data showed significant improvement with...
by Peter Ciszewski | Jun 23, 2020
Kathleen Hawker, MD, Group Medical Director at Genentech, describes two abstracts presented at the European Academy of Neurology Congress (EAN 2020) showing the benefits of the drug satralizumab to treat adolescent and adult patients with neuromyelitis optica...
by Peter Ciszewski | Jun 22, 2020
Steve Noga, MD of Takeda Oncology discusses the results of the phase 3 TOURMALINE-MM4 clinical trial, evaluating ixazomib as maintenance therapy for multiple myeloma. The results of this study were recently published for the European Hematology Association...
by Peter Ciszewski | Jun 19, 2020
The US Food and Drug Administration (FDA) has approved Cyrstiva (burosumab) to treat patients with tumor-induced osteomalacia. TIO is a rare paraneoplastic condition commonly characterized by bone pain, muscle weakness and fractures. These tumors secrete excess...
by Peter Ciszewski | Jun 18, 2020
Robert Rifkin, MD of the Rocky Mountain Cancer Center in Denver CO describes the real-world study he presented at the European Hematology Association (EHA) Annual Meeting that used fitbit and quality of life measures to assess whether multiple myeloma patients...
